South America Sodium-Glucose-Cotransport-2 (SGLT2) Inhibitor Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Sodium-Glucose-Cotransport-2 (SGLT2) Inhibitor Market Trends and Insights

Rising Type 2 Diabetes and Cardiorenal Disease Burden

The diabetes burden provided a sustained foundation for the South American SGLT2 inhibitor market. The International Diabetes Federation reported that 35 million adults in South and Central America had diabetes in 2024, resulting in 224,000 diabetes-related deaths and USD 81 billion in related expenditure. The 30.4% undiagnosed rate highlighted a significant untreated population, while the adult diabetes population was projected to reach 52 million by 2050. Brazil had 17 million adults with diabetes, and Argentina had 4.3 million adults with diabetes and a 14% adult prevalence rate, supporting treatment expansion as more patients entered formal care pathways.^{[1]Magliano DJ, Boyko EJ, “Diabetes Atlas,” International Diabetes Federation, ncbi.nlm.nih.gov}

Expansion of SGLT2 Use Beyond Glycemic Control

SGLT2 inhibitors increasingly served as cardiorenal therapies beyond their role as glucose-lowering medicines. The 2024 KDIGO guideline recommended these medicines for patients with chronic kidney disease and an estimated glomerular filtration rate (eGFR) of at least 20 mL/min/1.73 m², including patients without diabetes. The International Society of Nephrology presented this approach in its 2025 SGLT2 inhibitor Cold Map, while Colombia's 2025 expert consensus identified dapagliflozin and empagliflozin as preferred options for chronic kidney disease with albuminuria of at least 200 mg/g.^{[2]International Diabetes Federation, “Diabetes in South and Central America 2024,” IDF Diabetes Atlas, diabetesatlas.org} These recommendations expanded prescribing across endocrinology, cardiology, and nephrology, strengthening access through hospital protocols, specialist education, and diagnostic testing.

Increasing Public and Private Sector Formulary Adoption

Formulary decisions acted as an immediate access driver for the South American SGLT2 inhibitor market. In February 2025, Brazil made dapagliflozin available free of charge through Farmácia Popular for eligible adults aged 65 years and older with type 2 diabetes and cardiovascular disease.^{[3]Kidney Disease Improving Global Outcomes, “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International Supplements, theisn.org} In March 2025, Peru added dapagliflozin 10 mg and empagliflozin 10 mg and 25 mg to its complementary essential medicines list, while Argentina mandated specified health coverage for empagliflozin, canagliflozin, or dapagliflozin under Resolution 2091/2025. These measures reduced patient cost barriers and expanded public procurement and insurance volumes, although coverage remained limited to specified clinical groups.

Evidence-Based Diabetes and Heart Failure Treatment Pathways

National guidelines translated clinical evidence into standardized prescribing pathways across the region. Colombia's 2025 clinical guideline recommended SGLT2 inhibitors as an add-on to metformin when patients did not achieve glycemic goals and supported their use as first-line cardiorenal protection for patients with established cardiovascular disease. The guideline positioned these medicines as preferred options for eligible patients with heart failure and diabetic kidney disease. Continuing medical education and digital chronic care models supported adoption beyond major tertiary centers and aligned diabetes, cardiology, and nephrology care for patients with overlapping conditions.

High Out-of-Pocket Cost and Uneven Reimbursement

High out-of-pocket costs continued to limit utilization outside major public coverage channels. In Argentina, price-reference mechanisms did not consistently keep pace with pharmacy costs during currency instability. Peru's 2025 essential medicines decision applied only to the public-sector framework, leaving private retail patients exposed to full medicine costs. This created varied demand patterns between subsidized public-sector and private-sector patients. Fragmented reimbursement and procurement structures further delayed access in smaller countries.

Urban-Rural Inequality in Specialist Diagnosis and Follow-Up

SGLT2 inhibitor prescribing for kidney disease and heart failure often requires eGFR and albuminuria testing. Rural primary care settings had lower access to these diagnostics than major metropolitan centers. In Brazil, high-complexity hospital networks supported the consistent implementation of approved diabetes protocols, while rural municipalities in the North and Northeast had limited specialist access. This gap affected diagnosis, follow-up, and the safe initiation of treatment. Telemedicine and pharmacy-led chronic care services expanded access, but availability remained uneven across regions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug: Dapagliflozin Leads Access Channels While Ertugliflozin Gains Through Late Entry

Dapagliflozin accounted for 38.56% of revenue in 2025, making it the leading molecule in the South America SGLT2 inhibitor market. Its position reflects early cardiorenal use and AstraZeneca's established access channels in Brazil and Argentina. Brazil's February 2025 Farmácia Popular decision created a subsidized volume base for eligible older adults with type 2 diabetes and cardiovascular disease. Empagliflozin held the second-largest position, supported by Boehringer Ingelheim's established Jardiance franchise. Canagliflozin has a smaller role, as dapagliflozin and empagliflozin are more embedded in public protocols and specialist practice.

Ertugliflozin is forecast to grow at a CAGR of 10.12% from 2026 to 2031. Its later entry provides scope to compete in markets where formularies for older therapies are established. Ipragliflozin and sotagliflozin address smaller cardiorenal patient groups, while sotagliflozin has a differentiated role in heart failure treatment for patients with type 2 diabetes. The market is also seeing more generic dapagliflozin products from EMS, Eurofarma, and Cristália. ANVISA's bioequivalence requirements support therapeutic quality as generic substitution expands.

By Indication: Type 2 Diabetes Remains the Volume Base While Chronic Kidney Disease Expands

Type 2 diabetes mellitus accounted for 41.86% of revenue in 2025 and remains the primary prescribing indication. The broad prevalence of cardiovascular comorbidities supports continued SGLT2 inhibitor use. Treatment pathways in Colombia, Brazil, and Argentina recommend these medicines for eligible patients with type 2 diabetes and cardiovascular conditions. Heart failure has gained importance as regional recognition expands across reduced- and preserved-ejection-fraction settings. Tertiary centers in São Paulo, Buenos Aires, and Bogotá are increasingly adopting multidisciplinary cardiorenal care models.

Chronic kidney disease is forecast to grow at a CAGR of 11.25% from 2026 to 2031. The South American SGLT2 inhibitor market size for this indication is supported by KDIGO recommendations for patients with an eGFR of at least 20 mL/min/1.73 m², regardless of diabetes status. The 2025 ISN Cold Map supports the clinical implementation of this approach. Cardiovascular risk reduction remains another key use case for high-risk patients. Other approved indications include emerging applications in type 1 diabetes and acute kidney injury prevention, although public formularies do not yet reflect these uses.

By Distribution Channel: Hospital Pharmacies Anchor Access While Online Pharmacies Grow

Hospital pharmacies accounted for 45.87% of distribution in 2025, reflecting specialist-led treatment initiation and monitoring for patients with complex kidney, heart failure, or cardiovascular conditions. Brazil's public procurement model channels significant institutional volumes through high-complexity hospital pharmacy networks. This channel favors manufacturers with hospital formulary access and institutional account capabilities. AstraZeneca and Boehringer Ingelheim have established relationships with major hospitals in Brazil, Argentina, and Colombia. Public health systems and retail pharmacies support patients as they transition to an ongoing medicine supply.

Online pharmacies are forecast to expand at a CAGR of 10.67% from 2026 to 2031. Digital dispensing supports recurring monthly refills for diabetes and chronic kidney disease treatment, while subscription models may reduce missed refills. The channel also reflects the growth of digital prescription services and pharmacy-led care models. Retail pharmacies remain important in Chile and Colombia, where private insurance channels play a larger role. The South American SGLT2 inhibitor market will continue to rely on institutional and community dispensing channels, with their relative importance varying by public coverage and pharmacy infrastructure.

Geography Analysis

Brazil held 52.30% of regional revenue in 2025. Its market position was supported by 17 million adults with diabetes, SUS procurement, and expanding generic availability. Farmácia Popular and CONITEC decisions established formal access pathways for defined dapagliflozin patient groups. ANVISA approved the first generic dapagliflozin plus metformin fixed-dose combination in May 2026. Lower prices reduced revenue per unit but could expand the treated patient population.

Argentina is forecast to record an 11.56% CAGR from 2026 to 2031. Resolution 2091/2025 requires coverage for eligible patients with type 2 diabetes and cardiovascular disease or diabetic nephropathy. Argentina had 4.3 million adults with diabetes and a 14% adult prevalence rate. The gap between clinical need and treatment utilization supports faster forecast growth. Colombia had 3 million adults with diabetes, and updated endocrinology guidance supports continued volume growth. Its regulatory and reimbursement pathways facilitate formulary discussions for innovative medicines.

Chile's 2024 multidisciplinary consensus supports SGLT2 use for heart failure, cardiovascular prevention in type 2 diabetes, and chronic kidney disease. However, its smaller scale limits its regional volume contribution. Peru's March 2025 essential medicines listing improved access conditions for dapagliflozin and empagliflozin, which were previously available mainly through private retail. Bolivia, Ecuador, and Paraguay have fragmented regulatory and procurement systems, limiting treatment penetration and resulting in gradual growth. In these countries, market growth remains dependent on local tender design, administrative capacity, and health technology assessment capabilities.